Multiple sclerosis and spasticity

Physical Medicine and Rehabilitation Clinics of North America

Volumn 16, Issue 2, 2005, Pages 467-481

  Haselkorn, Jodie K ^a,b,c,d   Loomis, Sharon ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMINOTRANSFERASE; BACLOFEN; BENZODIAZEPINE; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; DANTROLENE; DIAZEPAM; GABAPENTIN; PHENOL; PLACEBO; TIZANIDINE;

CLINICAL EXAMINATION; CLINICAL TRIAL; DIARRHEA; DISABILITY; DIZZINESS; DROWSINESS; FALLING; FATIGUE; HALLUCINATION; HEALTH STATUS; HUMAN; JOINT CHARACTERISTICS AND FUNCTIONS; LETHARGY; LIVER TOXICITY; MOTOR COORDINATION; MULTIPLE SCLEROSIS; MUSCLE STRETCHING; MUSCLE WEAKNESS; NAUSEA; NEUROMUSCULAR BLOCKING; OCCUPATIONAL THERAPY; PATHOPHYSIOLOGY; PHYSIOTHERAPY; PRIORITY JOURNAL; RATING SCALE; REVIEW; SEDATION; SIDE EFFECT; SPASTICITY; SPEECH DISORDER; TOXIC HEPATITIS; WELLBEING; XEROSTOMIA;

EXERCISE THERAPY; HUMANS; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; NEUROMUSCULAR BLOCKADE; PATIENT CARE PLANNING;

EID: 18944370008     PISSN: 10479651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmr.2005.01.006     Document Type: Review

References (64)

1. K.J. Avourou, E. Goldenberg, and G. Cleghon Sociodemographic and health status characteristics of persons with MS and their caregivers Multiple Sclerosis Management 3 1 1996 6 17
2. G. Brichetto Symptomatic medication in use in multiple sclerosis Mult Scler 9 5 2003 458 460
3. M.P. Barnes Spasticity in multiple sclerosis Neurorehabil Neural Repair 17 1 2003 66 70
4. D.T. Shakespeare, M. Boggild, and C. Young Anti-spasticity agents for multiple sclerosis Cochrane Database of Syst Rev 4 2001 CD001332
5. S. Beard, A. Hunn, and J. Wight Treatments for spasticity and pain in multiple sclerosis: a systematic review Health Technol Assess 7 40 2003 1 111
6. Haselkorn JK, et al. Spasticity management in multiple sclerosis: evidence-based management strategies for spasticity treatment in multiple sclerosis. Multiple Sclerosis Council for Clinical Practical Guidelines. 2003: Consortium of Multiple Sclerosis Centers.
7. R.D. Penn Intrathecal baclofen for severe spinal spasticity New Engl J Med 320 23 1989 1517 1521
8. B. Ashworth Preliminary trial of carisoprodol in multiple sclerosis Practitioner 192 1964 540 542
9. R.W. Bohannon, and M.B. Smith Interrater reliability of a modified Ashworth scale of muscle spasticity Phys Ther Rev 67 1987 206 207
10. J.A. Freeman The impact of inpatient rehabilitation on progressive multiple sclerosis Ann Neurol 42 2 1997 236 244
11. A. Solari Physical rehabilitation has a positive effect on disability in multiple sclerosis patients Neurology 52 1999 57 62
12. B.L. Boynton, and P.M. Garramone Observations on the effects of cool baths for patients with multiple sclerosis Phys Ther Rev 39 1959 297 299
13. O.D. Pinto, M. Polker, and G. Debono Results of international clinical trials with lioresal Postgrad Med J 48 Suppl 5 1972 18 23
14. B. Brouwer, and V. Sousa de Andrade The effects of slow stroking on spasticity in patients with multiple sclerosis; a pilot study Physiotherapy Theory & Practice 11 1 1995 13 21
15. C.W. Watson Effect of lowering body temperature on the symptoms and signs of multiple sclerosis New Engl J Med 261 1959 1253 1259
16. O. Miglietta Evaluation of cold in spasticity Am J Phys Med 41 1962 148 151
17. J. Kinnman Temporary improvement of motor function in patients with multiple sclerosis after treatment with a cooling suit J Neurol Rehabil 11 2 1997 109 114
18. J. Rosche The effects of therapy on spasticity utilizing a motorized exercise-cycle Spinal Cord 35 3 1997 176 178
19. J. Little, and T. Massagli Spasticity and associated abnormalities of muscle tone J. DeLisa Rehabilitation medicine, principles and practice 3rd edition 2004 Lippincott Seattle 1006 1007
20. K.R. Bell, and F. Williams Use of botulinum toxin type A and type B for spasticity in upper and lower limb Am J Phys Med 14 4 2003 821 835
21. B.J. Snow Treatment of spasticity with botulinum toxin: a double-blind study Ann Neurol 28 4 1990 512 515
22. N. Hyman Botulinum toxin [Dysport] treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study J Neurol Neurosurg Psychiatry 68 6 2000 707 712
23. G.E. Francisco Botulinum toxin: dosing and dilution Am J Phys Med 83 Suppl 10 2004 S30 S37
24. J.F. Nielsen, J.B. Anderson, and T. Sinkjaer Baclofen increases the soleus stretch reflex threshold in the early swing phase during walking in spastic multiple sclerosis patients Mult Scler 6 2 2000 105 114
25. A. From, and A. Heltberg A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis Acta Neurol Scand 51 2 1975 158 166
26. W. Cendrowski, and W. Sobczyk Clonazepam, baclofen and placebo in the treatment of spasticity Eur Neurol 16 1-6 1977 257 262
27. G.B. Orsnes Effect of baclofen on gait in spastic MS patients Acta Neurol Scand 101 4 2000 244 248
28. J.F. Nielsen, and T. Sinkjaer Peripheral and central effect of baclofen on ankle joint stiffness in multiple sclerosis Muscle Nerve 23 1 2000 98 105
29. G.M. Sawa, and D.W. Paty The use of baclofen in treatment of spasticity in multiple sclerosis Can J Neurol Sci 6 3 1979 351 354
30. J.V. Basmajian Lioresal (baclofen) treatment of spasticity in multiple sclerosis Am J Phys Med 54 4 1975 175 177
31. S.P. Brar Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis Arch Phys Med Rehabil 72 3 1991 186 189
32. Y.D. Lapierre, R. Elie, and L. Tetreault The antispastic effects of Ba 34647 (B-4-p-Chlorophenyl-gamma-amino-butyric Acid) a GABA derivative Curr Therapeutic Res Clin Exper 16 10 1974 1059 1068
33. R.G. Feldman Baclofen for spasticity in multiple sclerosis: double-blind crossover and three-year study Neurology 28 11 1978 1094 1098
34. B.A. Sachais, J.N. Logue, and M.S. Carey Baclofen, a new antispastic drug: a controlled, multicenter trial in patients with multiple sclerosis Arch Neurol 34 7 1977 422 428
35. J.V. Basmajian, and V. Yucel Effects of a GABA-derivative (BA-34647) on spasticity: preliminary report of a double-blind cross-over study Am J Phys Med 53 5 1974 223 228
36. D.W. Hedley, J.A. Maroun, and M.L. Espir Evaluation of baclofen (Lioresal) for spasticity in multiple sclerosis Postgrad Med J 51 599 1975 615 618
37. M.C. Hoogstraten Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients Acta Neurol Scand 77 3 1988 224 230
38. C. Smolenski, S. Muff, and S. Smolenski-Kautz A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis Curr Med Res Opin 7 6 1981 374 383
39. R. Stein The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spasticity drug tizanidine compared with baclofen Acta Neurol Scand 75 1987 190 194
40. B. Bass Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis Can J Neurol Sci 15 1 1988 15 19
41. G.P. Rice Tizanidine vs. baclofen in the treatment of spasticity in patients with multiple sclerosis Can J Neurol Sci 16 4 1989 451
42. M. Eyssette Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis Curr Med Res Opin 10 10 1988 699 708
43. L. Sheplan, and C. Ishmael Spasmolytic properties of dantrolene sodium: clinical evaluation Mil Med 140 1 1975 26 29
44. M. Emre Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud) J Neurol Neurosurg Psychiatry 57 11 1994 1355 1359
45. P.W. Nance Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis Arch Neurol 54 6 1997 731 736
46. United Kingdom Tizanidine Trial Group A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group Neurology 44 11 Suppl 9 1994 S70 S79
47. Y. Lapierre Treatment of spasticity with tizanidine in multiple sclerosis Can J Neurol Sci Suppl 14 3 1987 513 517
48. C. Smith Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group Neurology 44 11 Suppl 9 1994 S34 S42 [discussion S42-3]
49. D. Gambi Dantrolene sodium in the treatment of spasticity caused by multiple sclerosis or degenerative myelopathies: a double-blind, crossover study in comparison with placebo Curr Therapeutic Res 33 1983 835 840
50. A.J. Gelenberg, and D.C. Poskanzer The effect of dantrolene sodium on spasticity in multiple sclerosis Neurology 23 12 1973 1313 1315
51. R.T. Schmidt, and R.H. Lee Treatment of spasticity in multiple sclerosis: comparison of dantrolene sodium and diazepam Trans Am Neurol Assoc 100 1975 235 237
52. R.T. Schmidt, R.H. Lee, and R. Spehlmann Comparison of dantrolene sodium and diazepam in the treatment of spasticity J Neurol Neurosurg Psychiatry 39 1976 350 356
53. U. Rinne Tizanidine treatment of spasticity in multiple sclerosis and chronic myelopathy Curr Therapeutic Res 28 1980 827 836
54. M.E. Mueller Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis Arch Phys Med Rehabil 78 5 1997 521 524
55. J.R. Coffey Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study J Neurosurg 78 2 1993 226 232
56. T.J. Postma Cost analysis of the treatment of severe spinal spasticity with a continuous intrathecal baclofen infusion system Pharmacoeconomics 15 4 1999 395 404
57. J. Dressnandt, and B. Conrad Lasting reduction of severe spasticity after ending chronic treatment with intrathecal baclofen J Neurol Neurosurg Psychiatry 60 2 1996 168 173
58. Y. Lazorthes Chronic intrathecal baclofen administration for control of severe spasticity J Neurosurg 72 3 1990 393 402
59. G.A. Ochs, and J.C. Tonn Functional outcome and clinical significance of long-term intrathecal baclofen therapy for severe spasticity J Neurol Rehabil 10 3 1996 159 166
60. J. Siegfried, and G.L. Rea Intrathecal application of drugs for muscle hypertonia Scand J Rehabil Med 17 1988 145 148
61. W.J.C. Becker Long-term intrathecal baclofen therapy in patients with intractable spasticity Can J Neurol Sci 22 3 1995 208 217
62. M.D. Smyth, and W.J. Peacock The surgical management of spasticity Muscle Nerve 23 2000 153 163
63. L. Jarrett, P. Nandi, and A.J. Thompson Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role? J Neurol Neurosurg Psychiatry 73 2002 705 709
64. K. Salome Surgical management of spasticity by selective posterior rhizotomy: 30 years of experience Isr Med Assoc J 5 8 2003 543 546